**PHENOTYPE REPORT**

**Animals with altered genetic make-up(manipulated, modified, naturally-occurring mutation)**

***Complete a separate Attachment for EACH strain.***

*Note:*

* *Specific approval may be required from the Institutional Biosafety Committee.*

*(See:* [*http://www.flinders.edu.au/research/researcher-support/ethics/committees/biosafety.cfm*](http://www.flinders.edu.au/research/researcher-support/ethics/committees/biosafety.cfm)*)*

1. AWC Project Number:

|  |
| --- |
|  |

2. IBC Reference Number:

|  |
| --- |
|  |

3. Please indicate which of the following is involved with this project:

|  |  |
| --- | --- |
|  | Use of an existing genetically modified strain of animal.  |
|  | Production/creation and use of a new genetically modified strain of animal (Including backcrossing onto a different background strain) |
|  | Use of animals with a naturally occurring mutation. |

4. Explain the relevance of the genetic modification to the project (**in plain English**).

|  |
| --- |
|  |

5. Which genes will be confirmed via genotyping?

|  |
| --- |
|  |

6. What will be the fate of animals that are not of the appropriate genotype?

|  |
| --- |
|  |

7. Animal Details

|  |  |
| --- | --- |
| Animal species |  |
| Background strain |  |
| **Select as applicable from the following:**[ ]  Knock-in strain[ ]  Knock-out strain[ ]  Transgenic strain[ ]  Mutant strain[ ]  Other – Please describe:  |

**Please add animal naming information in Table 1 on the last page of this report.**

8. How much is known about the biological characteristics/phenotype of this strain?

|  |  |
| --- | --- |
|  | Well characterised |
|  | Partially-characterised/some information available |
|  | Unknown |

9. Where was this genetically modified animal created, or mutant animal discovered (by whom/which organisation, etc.)? Reference if possible

|  |
| --- |
|  |

10. How many generations of this strain have been produced or what year was the animal created?

|  |
| --- |
|  |

11. Is the genetic modification/mutation stable? If NO, provide details.

|  |
| --- |
|  |

12. Briefly describe the function of the gene(s) that have/will be modified or have mutated.

|  |
| --- |
|  |

13. What organs/tissues are affected (eg. gene expressed in liver only).

|  |
| --- |
|  |

14. What abnormalities are known to exist, or do you expect, in these animals (eg. behaviour, physiology, reproductive or developmental measures). Include age at onset of symptoms / phenotype characteristics, if appropriate. Your answer to this question should inform the AEC about abnormalities or changes which have a welfare impact.

|  |
| --- |
|  |

**BREEDING**

15. Detail any problems with the breeding of these animals

|  |
| --- |
|  |

16. How are these animals bred? (eg. mating of Homozygote X Heterozygote, Wild type X Heterozygote, backcrossing to Wild type).

|  |
| --- |
|  |

17. Is any special feeding, handling or isolation of the animals required? (eg. Quarantine or Barrier for immune-compromised animals, special diet, a delay in weaning until mice are 4 weeks of age).

|  |
| --- |
|  |

**ANIMAL FACILITY TO COMPLETE QUESTIONS 18 to 20, RESEARCHERS PROCEED TO ‘HOUSING’ SECTION:**

|  |  |  |  |
| --- | --- | --- | --- |
| 18. What is the average litter size?

|  |
| --- |
|  |

19. What is the pre-weaning mortality?

|  |
| --- |
|  |

20. What is the post-weaning mortality?

|  |
| --- |
|  |

 |

**HOUSING**

21. Detail any problems associated with the housing or use of these animals.

|  |
| --- |
|  |

22. Provide details of any special husbandry or specialist care to be provided to the animals to minimise the impact of any adverse effect from the genetic modification/ mutation.

|  |
| --- |
|  |

**MONITORING**

23. Describe any adverse effects, pain or distress, and/or unexpected mortality, the causes if known and how these problems will be managed/resolved. If none this should be indicated.

|  |
| --- |
|  |

24. Have you attached a specific monitoring checklist with appropriate endpoints for monitoring the effect of the genetic modification/ mutation on the welfare of these animals? If NO, why not?

*Note: Detailed monitoring protocols for the detection of expected and unexpected adverse effects in these animals* ***must be provided****.*

|  |
| --- |
|  |

**TABLE 1: ANIMAL NAMING:**

|  |  |
| --- | --- |
| **Animal strain name used in AWC application** |  |
| **Animal strain name used in IBC application** |  |
| **Alternate names for this strain**  |  |
| **Strain name that will be used on cage card** |  |
| **Link to strain information on supplier’s website (e.g. JAX, Riken, Charles River)** **(if applicable)** |  |
| **JAX stock number (if applicable)** |  |